Chemed (NYSE:CHE) Given New $510.00 Price Target at Bank of America

Chemed (NYSE:CHE) had its price target upped by Bank of America from $450.00 to $510.00 in a research report report published on Thursday,Benzinga reports. Bank of America currently has a neutral rating on the stock.

Several other equities research analysts have also commented on CHE. Royal Bank Of Canada raised their price target on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research note on Monday, April 27th. Wall Street Zen lowered Chemed from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Weiss Ratings upgraded Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Finally, Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $480.25.

Chemed Stock Up 2.2%

Chemed stock opened at $490.11 on Thursday. The company has a 50-day simple moving average of $441.89 and a 200-day simple moving average of $428.28. The firm has a market capitalization of $6.50 billion, a P/E ratio of 26.71, a P/E/G ratio of 1.77 and a beta of 0.52. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.83 and a current ratio of 0.85. Chemed has a one year low of $365.20 and a one year high of $492.30.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 earnings per share for the quarter, beating the consensus estimate of $5.30 by $0.35. The firm had revenue of $657.51 million for the quarter, compared to the consensus estimate of $659.22 million. Chemed had a net margin of 10.23% and a return on equity of 27.18%. Chemed’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the firm posted $5.63 EPS. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, equities analysts expect that Chemed will post 22.67 earnings per share for the current year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, May 28th. Chemed’s dividend payout ratio (DPR) is presently 13.08%.

Insiders Place Their Bets

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the sale, the chief executive officer owned 90,219 shares in the company, valued at $37,993,927.47. This represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Andrea R. Lindell sold 1,347 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total value of $602,553.51. Following the completion of the sale, the director owned 4,578 shares of the company’s stock, valued at approximately $2,047,876.74. This trade represents a 22.73% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 3.33% of the company’s stock.

Institutional Investors Weigh In On Chemed

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Monetary Solutions Ltd bought a new position in shares of Chemed during the 4th quarter valued at about $25,000. Los Angeles Capital Management LLC acquired a new position in shares of Chemed in the 4th quarter worth approximately $26,000. BOK Financial Private Wealth Inc. bought a new stake in shares of Chemed in the 4th quarter worth approximately $27,000. Versant Capital Management Inc raised its holdings in shares of Chemed by 7,500.0% in the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock worth $35,000 after purchasing an additional 75 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in Chemed by 65.3% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock valued at $38,000 after purchasing an additional 32 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.